1.Title<\/p>\r\n
\u201cMethod and composition for decreasing the psychotomimetic side effect and addictive disorder of ketamine\u201d (abbreviated as \u201cThe Technology\u201d) available for technology licensing.<\/p>\r\n
2.Description:<\/p>\r\n
The present invention relates to a method for reducing the addictive andpsychotomimetic side effects of ketamine and enhancing the medical efficacy of ketamine. It is characterized by using ketamine in combination withmethylglycine derivatives for administration<\/p>\r\n
3.Potential collaboration partner qualifications:<\/p>\r\n
(1)\u00a0\u00a0\u00a0\u00a0\u00a0be incorporated and approved by law and does not have any record of misconduct or conviction for any offense<\/p>\r\n
(2)\u00a0\u00a0\u00a0\u00a0\u00a0better to have related experience and skills for developing The Technology<\/strong><\/p>\r\n (3)\u00a0\u00a0\u00a0\u00a0\u00a0better to have experience of international collaboration and clinical trial<\/p>\r\n (4)\u00a0\u00a0\u00a0\u00a0\u00a0better to be ready to invest or be able to raise the funds<\/p>\r\n 4.Registration\uff1a<\/p>\r\n Please contact to Mr. Patrick Liu or Ms. Wen-Chuan Hsieh (Address: Technology Transfer and Incubation Center, National Health Research Institutes, 35 Keyan Road, Zhunan Town, Miaoli County 35053, Taiwan, R.O.C., Tel: +88637<\/a>-246166#33206\/33209, E-mail: jcliu@nhri.edu.tw;<\/a> wenchuan@nhri.edu.tw<\/a> ) before Aug 4, 2020.<\/p>\r\n 5.Other:<\/p>\r\n NHRI retains the right to modify and terminate this announcement.<\/p>\r\n For detailed status of The Technology<\/strong>, please contact to the case officer.<\/p>\r\n Attachments:<\/p>\r\n I:\u00a0 Announcement<\/a><\/p>\r\n